CR Boya Revenue Rises but Profit Slumps as China Resources Pharma Unit Proposes Dividend

China Resources Pharmaceutical Group Ltd. ( (HK:3320) ) has shared an announcement.

China Resources Pharmaceutical has disclosed key 2025 financial data for its Shenzhen-listed subsidiary China Resources Boya Bio-pharmaceutical, which remains under its control via a 30.48% equity stake and 41.79% voting rights. The unit operates in the bio-pharmaceutical segment, contributing to the group’s exposure to specialized therapies and the mainland China healthcare market.

For 2025, Boya reported a modest 2.68% rise in total assets and an 18.69% increase in revenue to about RMB2.06 billion, but net profit attributable to shareholders plunged 71.61%, with core profit excluding extraordinary items turning slightly negative. Operating cash flow dropped nearly 80%, and earnings per share fell sharply, yet the board still proposed a cash dividend of RMB0.73 per 10 shares, signaling a commitment to shareholder returns despite pressure on profitability and cash generation, though the figures do not reflect the full financial position of the parent group.

The most recent analyst rating on (HK:3320) stock is a Hold with a HK$5.00 price target. To see the full list of analyst forecasts on China Resources Pharmaceutical Group Ltd. stock, see the HK:3320 Stock Forecast page.

More about China Resources Pharmaceutical Group Ltd.

China Resources Pharmaceutical Group Ltd. is a Hong Kong–incorporated pharmaceutical conglomerate with a portfolio spanning manufacturing and distribution of medicines and health products. Through its subsidiary China Resources Boya Bio-pharmaceutical Group, listed in Shenzhen, it is also active in bio-pharmaceuticals, where it holds a significant minority stake but majority voting rights, consolidating Boya as a subsidiary.

Average Trading Volume: 9,663,369

Technical Sentiment Signal: Sell

Current Market Cap: HK$29.15B

For a thorough assessment of 3320 stock, go to TipRanks’ Stock Analysis page.